Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on December 19, 2025. The report addresses the convening and subsequent adjournment of the Company's 2025 Annual Meeting of Stockholders due to a lack of quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate governance and does not contain financial statement data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the procedural adjournment of the Annual Meeting. No business was conducted at the initial meeting on December 19, 2025.
Outlook, Management Commentary, and Risks
- Meeting Adjournment: The Annual Meeting was adjourned because there were not enough shares present or represented by proxy to constitute a quorum.
- Reconvened Meeting: The meeting will reconvene on December 31, 2025, at 10:00 am Central Time.
- Format: The reconvened meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/SLRX2025.
- Proposals: No changes have been made to the proposals described in the Definitive Proxy Statement filed on November 7, 2025.
- Record Date: The record date for voting eligibility remains the close of business on October 24, 2025.
- Proxy Status: Proxies previously submitted will be voted at the reconvened meeting unless properly revoked; stockholders who have already voted need not take further action.
Investor Verification Checklist
- Verify the reconvened meeting date and time: December 31, 2025, at 10:00 am Central Time.
- Confirm the virtual webcast URL for the reconvened meeting.
- Review the Definitive Proxy Statement (filed November 7, 2025) for the specific proposals to be voted on.
- Check if previously submitted proxies remain valid or if revocation is necessary.